

In the Claims:

1. (currently amended) A film-shaped administration form for transmucosal administration of at least one active substance comprising:

a base mass for producing said administration form, said base mass comprising a ~~solvent or a mixture of solvents~~, at least one matrix-forming polymer and at least one active substance, said base mass having a pH value in the presence of water or of a water-containing solvent mixture, wherein said administration form is a dried film, and wherein, during the production of said administration form, the pH value of the base mass for producing said administration form ~~having been~~ is approximated or adapted to the physiological pH value of the mucosa to which the administration form is to be applied ~~during the production of said administration form~~, and wherein said at least one active substance is selected from the group consisting of pharmaceutically active substances and aroma substances.

2. (cancelled)

3. (currently amended) The administration form according to claim 1, wherein the matrix-forming polymer is selected from the group consisting of polyvinyl alcohol; cellulose derivatives; starch and starch derivatives; gelatine; polyvinyl pyrrolidones; ~~gum arabic~~; pullulan; ~~acrylates~~; dextran; polyacrylic acid; polyacrylates; polyethylene oxide polymers; polyacrylamides; ~~polyethylene glycol~~; collagen; alginates; pectins; ~~tragacanth~~; chitosan; alginic acid; arabinogalactan; galactomannan; agar-agar; agarose; carrageenan; and natural gums.

4. (previously presented) The administration form according to claim 1, wherein the polymer portion is 5 to 95%-wt. relative to the dry mass of the administration form.

5. (previously presented) The administration form according to claim 1, wherein the content of said pharmaceutically active substance is 0.1 to 50%-wt., relative to the dry mass of the administration form.
6. (previously presented) The administration form according to claim 1, wherein the content of said aroma substance is 0.1 to 20%-wt., relative to the dry mass of the administration form.
7. (previously presented) The administration form according to claim 1, wherein the pH value of the base mass having been approximated or adapted to a value in the range between 5 and 9.
8. (previously presented) The administration form according to claim 1, wherein the pH value was approximated or adapted by using a chemical selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, phosphoric acid and a buffer system.
9. (previously presented) The administration form according to claim 1, wherein said administration form is mucoadhesive.
10. (previously presented) The administration form according to claim 1, wherein said administration form is disintegratable.
11. (previously presented) The administration form according to claim 10, wherein said administration form disintegrates within 15 minutes after having been introduced in an aqueous medium.
12. (previously presented) Administration form according to claim 1, wherein said administration form is multilayered.

13. (previously presented) The administration form according to claim 1, wherein said administration form contains at least one adjuvant selected from the group consisting of filling agents, colourants, flavourings, aroma substances, fragrant substances, emulsifiers, plasticizers, sweeteners, preservatives, permeation-enhancing substances, and antioxidants.

14. (previously presented) The administration form according to claim 13, wherein the portion of said at least one adjuvant amounts to up to 30%-wt. relative to the dry mass of the administration form.

15. (currently amended) ~~Use of the~~ A method for transmucosal administration of active substances, comprising the step of applying an administration form according to claim 1 to a mucosa of a person or of an animal for at use selected from the group of applications consisting of oral, gingival, vaginal and rectal application.

16. (withdrawn) A process for the production of a film-shaped administration form for transmucosal administration of at least one active substance, comprising the steps of:

preparing a base mass comprising a solvent or a mixture of solvents, at least one matrix-forming polymer and at least one active substance;

approximating or adapting the pH value of the base mass to the physiological pH value of the mucous membrane to which the administration form is to be applied;

extruding the base mass to form a moist film;

drying the moist film; and

singularizing the administration form; wherein

said at least one active substance eing is selected from the group consisting of pharmaceutically active substances and aroma substances.

17. (withdrawn) The process according to claim 16, comprising the step of using water as the solvent or as at least one of the solvents of the mixture of solvents.

18. (withdrawn) The process according to claim 16, wherein the step of approximating or adapting the pH value of the base mass comprises the step of adjusting the pH value of the base mass to a value in the range between 5 and 9.

19. (withdrawn) The process according to claim 18, wherein the step of adjusting the the pH value is accomplished by adding a chemical selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, phosphoric acid and a buffer system.

20. (previously presented) The administration form according to claim 3, wherein said cellulose derivatives are selected from the group consisting of such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl ethyl cellulose, carboxymethyl cellulose, ethyl cellulose and propyl cellulose.

21. (previously presented) The administration form according to claim 4, wherein the polymer portion is 15 to 75%-wt. relative to the dry mass of the administration form.

22. (previously presented) The administration form according to claim 5, wherein the content of said pharmaceutically active substance is 0.5 to 20%-wt. relative to the dry mass of the administration form.

23. (previously presented) The administration form according to claim 6, wherein the content of said aroma substance is 1 to 10%-wt. relative to the dry mass of the administration form.
24. (previously presented) The administration form according to claim 7, wherein the pH value of the base mass was adjusted to a value in the range between 6 and 8.5.
25. (previously presented) The administration form according to claim 24, wherein the pH value of the base mass was adjusted to a value in the range between 6.5 and 8.
26. (previously presented) The administration form according to claim 8, wherein said buffer system is a phosphate buffer.
27. (previously presented) The administration form according to claim 11, wherein said administration form disintegrates within 3 minutes after having been introduced in an aqueous medium.
28. (previously presented) The administration form according to claim 27, wherein said administration form disintegrates within 60 seconds after having been introduced in an aqueous medium.
29. (previously presented) The administration form according to claim 13, wherein the portion of said at least one adjuvant amounts to up to 1 to 20%-wt. relative to the dry mass of the administration form.
30. (withdrawn) The process according to claim 18, comprising the step of adjusting the pH value of the base mass to a value in the range between 6 and 8.5.
31. (withdrawn) The process according to claim 30, comprising the step of adjusting the pH value of the base mass to a value in the range between 6.5 and 8.

32. (withdrawn) The process according to claim 19, wherein said buffer system is a phosphate buffer.

33. (new) The administration form according to claim 1, wherein said at least one active substance is selected from the group consisting of salts of said pharmaceutically active substances.

34. (new) The administration form according to claim 33, wherein said salts comprise hydrochlorides, citrates and salicylates.

35. (new) The administration form according to claim 1, wherein said at least one active substance is selected from the group consisting of aroma substances, without a pharmaceutical active substance being included in the administration form.

36. (new) The method according to claim 15, wherein said mucosa is selected from the group consisting of oral mucosa, gingival mucosa, vaginal mucosa, nasal mucosa and rectal mucosa.